Indication
Primary Peritoneal Serous Adenocarcinoma
15 clinical trials
15 products
9 drugs
Clinical trial
Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Terminated, Estimated PCD: 2022-09-27
Drug
AtezolizumabProduct
EmactuzumabDrug
TiragolumabClinical trial
GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262Status: Active (not recruiting), Estimated PCD: 2015-12-01
Product
BevacizumabProduct
CarboplatinClinical trial
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2027-03-17
Drug
GemcitabineClinical trial
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
AbraxaneClinical trial
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2018-10-31
Product
CediranibProduct
OlaparibClinical trial
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2022-07-07
Clinical trial
Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant EffusionStatus: Recruiting, Estimated PCD: 2025-12-01
Product
PegcetacoplanProduct
PembrolizumabClinical trial
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)Status: Active (not recruiting), Estimated PCD: 2019-04-30
Drug
AN0025Drug
DocetaxelClinical trial
A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2021-07-27
Clinical trial
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2019-04-04
Drug
TucidinostatProduct
TamoxifenProduct
TopotecanProduct
TrametinibClinical trial
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
olaparibClinical trial
A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast CancerStatus: Completed, Estimated PCD: 2020-07-29
Product
OnalespibClinical trial
Laparoscopic Cytoreduction After Neoadjuvant ChemotherapyStatus: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2026-12-30
Drug
mFOLFOX6